Zacks Investment Research upgraded shares of Shire PLC (NASDAQ:SHPG) from a sell rating to a hold rating in a research report sent to investors on Friday, October 27th.
According to Zacks, “The approval of Mydayis is likely to boost Shire’s ADHD segment dominance while strong performance of Vyvanse, Cinryze and Elaprase will continue to drive Shire’s top line. The label expansion of Cinryze in paediatrics and conditional approval of Natpara in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology portfolio, acquiring roughly 23% of the total market by the end of Jun 2017. However, the adult ADHD space is one of the largest and fastest growing segments of the market but is highly genericized. Moreover, shares have underperformed the industry so far this year. Estimates have risen ahead of Q3 earnings. The company has a mixed record of earnings surprises in recent quarters.”
Other analysts also recently issued reports about the stock. BidaskClub downgraded shares of Shire PLC from a hold rating to a sell rating in a research note on Saturday, July 1st. Cantor Fitzgerald set a $222.00 target price on shares of Shire PLC and gave the company a buy rating in a research note on Saturday, July 1st. HSBC Holdings plc raised shares of Shire PLC from a reduce rating to a hold rating in a research note on Thursday, July 6th. ValuEngine raised shares of Shire PLC from a hold rating to a buy rating in a research note on Thursday, July 6th. Finally, Stifel Nicolaus reaffirmed a buy rating and issued a $245.00 price target on shares of Shire PLC in a research note on Wednesday, July 12th. One analyst has rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the stock. Shire PLC presently has an average rating of Hold and a consensus price target of $211.00.
Shire PLC (NASDAQ SHPG) traded down $2.46 on Friday, reaching $137.90. The company’s stock had a trading volume of 129,761 shares, compared to its average volume of 1,137,305. The firm has a market capitalization of $42,167.93, a P/E ratio of 9.65, a price-to-earnings-growth ratio of 0.78 and a beta of 1.60. Shire PLC has a 12-month low of $137.80 and a 12-month high of $192.15. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.98 and a quick ratio of 0.52.
Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.64 by $0.17. The company had revenue of $3.70 billion for the quarter. Shire PLC had a return on equity of 14.41% and a net margin of 10.95%. Shire PLC’s quarterly revenue was up 7.1% on a year-over-year basis. During the same period in the prior year, the company posted $3.17 EPS. research analysts predict that Shire PLC will post 15 earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of the stock. Harding Loevner LP raised its position in Shire PLC by 18,894.4% in the third quarter. Harding Loevner LP now owns 127,537,052 shares of the biopharmaceutical company’s stock worth $20,354,000 after purchasing an additional 126,865,607 shares in the last quarter. Maverick Capital Ltd. raised its position in Shire PLC by 19.9% in the second quarter. Maverick Capital Ltd. now owns 1,942,087 shares of the biopharmaceutical company’s stock worth $320,969,000 after purchasing an additional 322,610 shares in the last quarter. Glenview Capital Management LLC raised its position in Shire PLC by 69.7% in the second quarter. Glenview Capital Management LLC now owns 1,722,977 shares of the biopharmaceutical company’s stock worth $284,756,000 after purchasing an additional 707,500 shares in the last quarter. Ameriprise Financial Inc. raised its position in Shire PLC by 6.4% in the third quarter. Ameriprise Financial Inc. now owns 1,606,342 shares of the biopharmaceutical company’s stock worth $245,997,000 after purchasing an additional 96,115 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in Shire PLC by 0.9% in the first quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock worth $268,773,000 after purchasing an additional 13,665 shares in the last quarter. 18.27% of the stock is owned by hedge funds and other institutional investors.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.